Astellas set for US and European mirabegron filings this year in OAB
This article was originally published in Scrip
Executive Summary
Astellas intends to file for US and European approval of its overactive bladder (OAB) treatment mirabegron this year following publication of Phase III results showing it significantly improves key OAB symptoms – urinary incontinence and frequency of micturition.